Low-dose intranasal insulin improves cognitive function and suppresses the development of epilepsy
Low-dose intranasal insulin improves cognitive function and suppresses the development of epilepsy
复制标题
DOI：
10.1016/j.brainres.2019.146474
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
Guohui Jiang
中科院分区：
文献类型：
--
作者：
Shu Peng;Jin Yang;Yufeng Wang;Yang Fan;Feng Tang;Changyue Hou;Juming Yu;Xiaoming Wang;Guohui Jiang
Intranasal insulin has neuroprotective effects on a variety of neurological diseases. Whether intranasal insulin affects epileptic activity and whether it has neuroprotective effects on epileptic diseases is however still unknown. Here we show that low-dose intranasal inhibits kainic acid (KA)- or pentylenetetrazole (PTZ)-induced acute seizures and reduced epileptic discharge activities in mice, potentially by alleviating the increase in seizure-induced glutamate in the hippocampus. Meanwhile, intranasal insulin increased GABA levels and the activities of hippocampal theta, which may affect the excitability of the hippocampus. In chronic KA-induced epilepsy, low-dose intranasal insulin reduces the frequency of SRSs seizures and epileptic discharges, while increases theta energy and thereby improved spatial memory. Larger doses of intranasal insulin increased the frequency of seizures, but did not aggravate cognitive impairment, suggesting that the frequency of seizures may not be related to impaired cognitive function. Overall, our findings show that low-dose intranasal insulin restrains epileptic events and improves cognitive impairment in epileptic mice, suggesting that learning and memory can be improved by intranasal insulin. However, larger doses might increase the risk of epileptic seizures.
